Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.
BACKGROUND: The phosphatase and tensin homolog-phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT) pathway is frequently altered in gynecological tumors, notably in endometrial. Despite this, evidence of clinical activity of PI3K inhibitors in endometrial cancer is poor and limited.
BACKGROUND: The phosphatase and tensin homolog-phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT) pathway is frequently altered in gynecological tumors, notably in endometrial. Despite this, evidence of clinical activity of PI3K inhibitors in endometrial cancer is poor and limited.
What the study was
- Study design
- Clinical Trial Phase II
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Why it surfaced
HIGH priority (score 8/10); study design: Clinical Trial Phase II; topic: Novel therapeutics: immunotherapy, CAR-T, targeted therapy; flag: PROMISING_PRELIMINARY
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.